Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 19Withdrawn 3Terminated 3Recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Adenocarcinoma of the Prostate 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Dutasteride × Clear all
NCT05705700 2023-02-27

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT01368003 2015-09-01

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Adenocarcinoma of the Prostate

NCT02159690 2015-01-26

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Johns Hopkins University

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡